<DOC>
	<DOC>NCT00351507</DOC>
	<brief_summary>This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosed with type 2 diabetes for at least 6 months Blood glucose criteria must be met BMI in the range 2240 History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes Use of thiazolidinediones or need for insulin within 3 months prior to screening Significant concomitant diseases or complications of diabetes High fasting triglycerides as defined by the protocol Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vildagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>